Developments of subunit and VLP vaccines against influenza a virus

Virologica Sinica

Volumn 27, Issue 3, 2012, Pages 145-153

  Deng, Ma Ping ^a   Hu, Zhi Hong ^a   Wang, Hua Lin ^a   Deng, Fei ^a  

^a WUHAN INSTITUTE OF VIROLOGY   (China)

Author keywords

Influenza; Recombinant expression; Subunit vaccine; VLP

Indexed keywords

ACAM FLU A; FLUNHANCE; INFLUENZA VACCINE; NUCLEOCAPSID PROTEIN; OSELTAMIVIR; PAPMV VP M2E; PROTEIN M2; SIALIDASE; UNCLASSIFIED DRUG; VACCINIA NP; VAX 125; VIRUS ANTIGEN; VIRUS HEMAGGLUTININ; VIRUS LIKE PARTICLE VACCINE; VSV NP; ZANAMIVIR;

ARTICLE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ENZYME ACTIVITY; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INFLUENZA A; INFLUENZA VIRUS A; NONHUMAN; PROTEIN EXPRESSION; TREATMENT RESPONSE; VACCINATION;

BIOTECHNOLOGY; HUMANS; INFLUENZA VACCINES; INFLUENZA, HUMAN; ORTHOMYXOVIRIDAE; TECHNOLOGY, PHARMACEUTICAL; VACCINES, SUBUNIT; VACCINES, SYNTHETIC; VACCINES, VIROSOME; VIRAL PROTEINS;

INFLUENZA A VIRUS; ORTHOMYXOVIRIDAE;

EID: 84863972224     PISSN: 16740769     EISSN: 1995820X     Source Type: Journal    
DOI: 10.1007/s12250-012-3241-1     Document Type: Article

References (54)

1. Altstein A D, Gitelman A K, Smirnov Y A, et al. 2006. Immunization with influenza a np-expressing vaccinia virus recombinant protects mice against experimental infection with human and avian influenza viruses. Arch Virol, 151(5): 921-931.
2. Barefoot B E, Sample C J, Ramsburg E A. 2009. Recombinant vesicular stomatitis virus expressing influenza nucleoprotein induces cd8 t-cell responses that enhance antibody-mediated protection after lethal challenge with influenza virus. Clin Vaccine Immunol, 16(4): 488-498.
3. Biesova Z, Miller M A, Schneerson R, et al. 2009. Preparation, characterization, and immunogenicity in mice of a recombinant influenza h5 hemagglutinin vaccine against the avian h5n1 a/vietnam/1203/2004 influenza virus. Vaccine, 27(44): 6234-6238.
4. Brands R, Visser J, Medema J, et al. 1999. Influvac: A safe madin darby canine kidney (mdck) cell culture-based influenza vaccine. Dev Biol Stand, 98: 93-100; discussion 111.
5. Brett I C, Johansson B E. 2005. Immunization against influenza a virus: Comparison of conventional inactivated, live-Attenuated and recombinant baculovirus produced purified hemagglutinin and neuraminidase vaccines in a murine model system. Virology, 339(2): 273-280. (Pubitemid 41169794)
6. Chen B J, Leser G P, Morita E, et al. 2007. Influenza virus hemagglutinin and neuraminidase, but not the matrix protein, are required for assembly and budding of plasmid-derived virus-like particles. J Virol, 81(13): 7111-7123. (Pubitemid 46986647)
7. Couch R B, Cate T R. 1983. Managing influenza in older patients. Geriatrics, 38(9): 61-74. (Pubitemid 13000915)
8. Cox M M. 2005. Cell-based protein vaccines for influenza. Curr Opin Mol Ther, 7(1): 24-29. (Pubitemid 40287452)
9. Cox M M, Hollister J R. 2009. Flublok, a next generation influenza vaccine manufactured in insect cells. Biologicals, 37(3): 182-189.
10. Cox M M, Patriarca P A,Treanor J. 2008. Flublok, a recombinant hemagglutinin influenza vaccine. Influenza Other Respi Viruses, 2(6): 211-219.
11. Cox M M J,Karl Anderson D. 2007. Production of a novel influenza vaccine using insect cells: Protection against drifted strains. Influenza Other Respi Viruses, 1(1): 35-40.
12. D'Aoust M A, Lavoie P O, Couture M M, et al. 2008. Influenza virus-like particles produced by transient expression in nicotiana benthamiana induce a protective immune response against a lethal viral challenge in mice. Plant Biotechnol J, 6(9): 930-940.
13. De Filette M, Martens W, Smet A, et al. 2008. Universal influenza a m2e-hbc vaccine protects against disease even in the presence of pre-existing anti-hbc antibodies. Vaccine, 26(51): 6503-6507.
14. Denis J, Acosta-Ramirez E, Zhao Y, et al. 2008. Development of a universal influenza a vaccine based on the m2e peptide fused to the papaya mosaic virus (papmv) vaccine platform. Vaccine, 26(27): 3395-3403.
15. Doherty P C, Turner S J, Webby R G, et al. 2006. Influenza and the challenge for immunology. Nat Immunol, 7(5): 449-455.
16. Fiers W, De Filette M, Birkett A, et al. 2004. A "universal" human influenza a vaccine. Virus Res, 103(1-2): 173-176.
17. Gavrilov V, Orekov T, Alabanza C, et al. 2011. Influenza virus-like particles as a new tool for vaccine immunogenicity testing: Validation of a neuraminidase neutralizing antibody assay. J Virol Methods, 173(2): 364-373.
18. Gerdil C. 2003. The annual production cycle for influenza vaccine. Vaccine, 21(16): 1776-1779. (Pubitemid 36398372)
19. Govorkova E A, Leneva I A, Goloubeva O G, et al. 2001. Comparison of efficacies of rwj-270201, zanamivir, and oseltamivir against h5n1, h9n2, and other avian influenza viruses. Antimicrob agents ch, 45(10): 2723-2732. (Pubitemid 32906663)
20. Grandea A G, Olsen O A, Cox T C, et al. 2010. Human antibodies reveal a protective epitope that is highly conserved among human and nonhuman influenza a viruses. Proc Natl Acad Sci USA, 107(28): 12658-12663.
21. Holmes E C, Ghedin E, Miller N, et al. 2005. Whole-genome analysis of human influenza a virus reveals multiple persistent lineages and reassortment among recent h3n2 viruses. Plos Biology, 3(9): e300.
22. Holsinger L J, Alams R. 1991. Influenza virus M2 integral membrane protein is a homotetramer stabilized by formation of disulfide bonds. Virology, 183(1): 32-43.
23. Holtz K M, Anderson D K, Cox M M J. 2003. Production of a recombinant influenza vaccine using the baculovirus expression vector system. Bioprocess J, 2: 25-32.
24. Bac-To-bac® baculovirus expression system. 2010. An efficient site-specific transposition system to generate baculovirus for high-level expression of recombinant proteins. Invitrogen. p1-69.
25. Johansson B, Kilbourne E. 1994. Immunization with purified n1 and n2 influenza virus neuraminidases demonstrates cross-reactivity without antigenic competition. Proc Natl Acad Sci USA, 91(6): 2358.
26. Johansson B E, Brett I C. 2007. Changing perspective on immunization against influenza. Vaccine, 25(16): 3062-3065. (Pubitemid 46482744)
27. Johansson B E, Price P M, Kilbourne E D. 1995. Immunogenicity of influenza-A virus n2 neuraminidase produced in insect larvae by baculovirus recombinants. Vaccine, 13(9): 841-845.
28. Johansson B E, Pokorny B A, Tiso V A. 2002. Supplementation of conventional trivalent influenza vaccine with purified viral n1 and n2 neuraminidases induces a balanced immune response without antigenic competition. Vaccine, 20(11-12): 1670-1674. (Pubitemid 34169810)
29. Khurana S, Wu J, Verma N, et al. 2011. H5n1 virus-like particle vaccine elicits cross-reactive neutralizing antibodies that preferentially bind to the oligomeric form of influenza virus hemagglutinin in humans. J Virol, 85(21): 10945-10954.
30. Kilbourne E D, Cerini C, Khan M, et al. 1987. Immunologic response to the influenza virus neuraminidase is influenced by prior experience with the associated viral hemagglutinin. I. Studies in human vaccinees. J Immunol, 138(9): 3010.
31. Kilbourne E D, Pokorny B A, Johansson B, et al. 2004. Protection of mice with recombinant influenza virus neuraminidase. J Infect Dis, 189(3): 459-461. (Pubitemid 38210582)
32. Lamb R, Krug R. 2001. Orthomyxoviridae: The viruses and their replication. In: Fields Virology. Knipe D N, Howley P M, Griffin D E, et al, ed. Philadelphia: Lippincott Williams and Wilkins Publishers, pp1487-1532.
33. Lopez-Macias C, Ferat-Osorio E, Tenorio-Calvo A, et al. 2011. Safety and immunogenicity of a virus-like particle pandemic influenza a (h1n1) 2009 vaccine in a blinded, randomized, placebo-controlled trial of adults in mexico. Vaccine, doi:10.1016/j.vaccine.2011.07.099.
34. Mahmood K, Bright R A, Mytle N, et al. 2008. H5n1 vlp vaccine induced protection in ferrets against lethal challenge with highly pathogenic h5n1 influenza viruses. Vaccine, 26(42): 5393-5399.
35. McKimm-Breschkin J, Trivedi T, Hampson A, et al. 2003. Neuraminidase sequence analysis and susceptibilities of influenza virus clinical isolates to zanamivir and oseltamivir. Antimicrob Agents Ch, 47(7): 2264-2272. (Pubitemid 36753582)
36. Mena I, Jambrina E, Albo C, et al. 1999. Mutational analysis of influenza a virus nucleoprotein: Identification of mutations that affect rna replication. J Virol, 73(2): 1186-1194. (Pubitemid 29036770)
37. Murphy B R, Kasel J A, Chanock R M. 1972. Association of serum anti-neuraminidase antibody with resistance to influenza in man. New Engl J Med, 286(25): 1329-1332.
38. Neumann G, Noda T, Kawaoka Y. 2009. Emergence and pandemic potential of swine-origin h1n1 influenza virus. Nature, 459(7249): 931-939.
39. Pau M G, Ophorst C, Koldijk M H, et al. 2001. The human cell line per.C6 provides a new manufacturing system for the production of influenza vaccines. Vaccine, 19(17-19): 2716-2721. (Pubitemid 32234294)
40. Pinto L H, Lamb R A. 2006. The m2 proton channels of influenza a and b viruses. J Biol Chem, 281(14): 8997-9000. (Pubitemid 43864610)
41. Pleschka S, Ludwig S, Wolff T, et al. 2006. Anti-viral approaches against influenza viruses. New Concepts of Antiviral Therapy, 115-167.
42. QIAexpressionist A. 2002. A handbook for high-level expression and purification of 6xhis-Tagged proteins. Qiagen. p1-125.
43. Quan F S, Huang C, Compans R W, et al. 2007. Virus-like particle vaccine induces protective immunity against homologous and heterologous strains of influenza virus. J Virol, 81(7): 3514-3524. (Pubitemid 46456660)
44. Roldao A, Mellado M C, Castilho L R, et al. 2010. Virus-like particles in vaccine development. Expert Rev Vaccines, 9(10): 1149-1176.
45. Schotsaert M, De Filette M, Fiers W, et al. 2009. Universal m2 ectodomain-based influenza a vaccines: Preclinical and clinical developments. Expert Rev Vaccines, 8(4): 499-508.
46. Sylte M J, Suarez D L. 2009. Influenza neuraminidase as a vaccine antigen. In:Vaccines for Pandemic Influenza. Compans R W, Orenstein W A, eds. Heidelberg: Springer, p227-241.
47. Szecsi J, Boson B, Johnsson P, et al. 2006. Induction of neutralising antibodies by virus-like particles harbouring surface proteins from highly pathogenic h5n1 and h7n1 influenza viruses. Virol J, 3: 70.
48. Treanor J J, Schiff G M, Hayden F G, et al. 2007. Safety and immunogenicity of a baculovirus-expressed hemagglutinin influenza vaccine: A randomized controlled trial. JAMA, 297(14): 1577-1582. (Pubitemid 46588371)
49. Wang K, Holtz K M, Anderson K, et al. 2006. Expression and purification of an influenza hemagglutinin-one step closer to a recombinant protein-based influenza vaccine. Vaccine, 24(12): 2176-2185. (Pubitemid 43255161)
50. Wang R, Song A, Levin J, et al. 2008. Therapeutic potential of a fully human monoclonal antibody against influenza a virus m2 protein. Antiviral Res, 80(2): 168-177.
51. Webster R G, Bean W J, Gorman O T, et al. 1992. Evolution and ecology of influenza-A viruses. Microbiol Rev, 56(1): 152-179.
52. Weldon W C, Wang B Z, Martin M P, et al. 2010. Enhanced immunogenicity of stabilized trimeric soluble influenza hemagglutinin. PLoS One, 5(9).
53. Wu C Y, Yeh Y C, Yang Y C, et al. 2010. Mammalian expression of virus-like particles for advanced mimicry of authentic influenza virus. PLoS One, 5(3): e9784.
54. Youil R, Su Q, Toner T J, et al. 2004. Comparative study of influenza virus replication in vero and mdck cell lines. J Virol Methods, 120(1): 23-31. (Pubitemid 38968653)